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Background: Prolonged dual antiplatelet therapy (DAPT) w/ clopidogrel+aspirin (≥1 year) has been recommended for all pts undergoing drug-
eluting stent (DES) implantation to prevent late stent thrombosis (ST). Whether such measure improves safety w/ Endeavor zotarolimus-eluting stent 
(ZES) - a 2nd generation DES w/ phosphorylcholine (a non-thrombogenic polymer with improved biocompatibility as compared to first generation 
DES Cypher/Taxus), remains controversial.
Methods: The OPTIMIZE trial is a prospective, randomized, multicenter, physician-initiative study designed to evaluate the impact of short-term 
(3-month) vs long-term (12-month) DAPT post-ZES in the real-world clinical practice. Pts will be randomized in a 1:1 ratio at 30 sites in Brazil, and 
sample size (n=3,120) has been powered to demonstrated non-inferiority of short-term vs long-term (standard therapy) DAPT on the combined 
1ry endpoint of: death, myocardial infarction, cerebral vascular accident, and major bleeding at 12-month follow-up. By protocol, there are no pre-
specified restrictions regarding the number of lesions/vessels that can be treated with the study device. Key exclusion criteria are: STEMI presenting 
for primary intervention, saphenous vein grafts, and prior DES implant. Data management (event adjudication) and angiographic analysis will be 
independently performed at the Cardiovascular Research Center, Sao Paulo, Brazil.
Results: A total of 413 pts have been enrolled and randomized to date (enrollment ongoing since April/2010).
Conclusions: The large, prospective, randomized, multicenter, physician-initiative OPTIMIZE trial will determine the implications of the DAPT 
duration in real-world pts undergoing percutaneous coronary intervention with Endeavor ZES. Complete blinded results of the first 600 pts will be 
presented at the meeting.
